Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Principal Financial Group Inc. increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 306,322 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,590 shares during the quarter. Principal Financial Group Inc. owned about 0.55% of Supernus Pharmaceuticals worth $10,032,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company’s stock worth $1,033,000 after acquiring an additional 1,083 shares in the last quarter. Two Sigma Advisers LP increased its stake in Supernus Pharmaceuticals by 14.7% during the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company’s stock valued at $282,000 after purchasing an additional 1,000 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company’s stock valued at $2,169,000 after purchasing an additional 3,495 shares in the last quarter. SG Americas Securities LLC increased its stake in Supernus Pharmaceuticals by 63.6% during the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company’s stock valued at $579,000 after purchasing an additional 6,867 shares in the last quarter. Finally, Norges Bank bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $4,540,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $33.96 on Tuesday. The firm has a market cap of $1.90 billion, a P/E ratio of 30.59 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $27.05 and a fifty-two week high of $40.28. The firm has a 50-day simple moving average of $32.26 and a two-hundred day simple moving average of $33.73.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.